RE:RE:Another off shelf CAR-T had durability problems " While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer (NK) cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types." - NKarta Biosciences.
https://www.nkartatx.com/about/
Perhaps NKarta's CEO Paul Hastings doesn't yet have a good understanding of CAR-T's potential in the treatment of solid tumors (in combination with ONCY's pelarerorep) when he claimed that NKarta's findings have “clouded the entire allogeneic cell therapy space”. Maybe his understanding needs to be further illuminated.